TB-500

TB-500 is a synthetic peptide analogue of the active region of Thymosin Beta-4 (Tβ4), a ubiquitous 43-amino acid protein involved in actin sequestration, cell migration, and tissue remodeling. Corresponding to the actin-binding domain (amino acids 17–23, sequence: Ac-LKKTETQ), TB-500 has been widely studied in preclinical research for its role in wound repair signaling, angiogenesis, and modulation of inflammatory pathways.

In vitro and in vivo research has demonstrated that Tβ4 and its active fragment facilitate cell motility by regulating the G-actin/F-actin equilibrium — a critical step in the migration of keratinocytes, endothelial cells, and fibroblasts toward sites of tissue injury. Additional research has investigated TB-500’s potential to promote integrin-linked kinase (ILK) activation and vascular endothelial growth factor (VEGF) upregulation, processes associated with neovascularization and capillary formation in ischemic tissue models.

Published preclinical studies have examined TB-500 and full-length Tβ4 across a range of research models including dermal wound healing, myocardial repair, hepatic fibrosis, and traumatic brain injury. Notable findings include accelerated wound closure in full-thickness rodent dermal models, improved cardiac function following experimentally induced infarction, and increased neurogenesis in CNS injury models — all subjects of ongoing academic investigation.

Each vial contains 10mg of TB-500 in lyophilized form, suitable for reconstitution with bacteriostatic water for laboratory research applications. Supplied as a white lyophilized powder. For reconstitution guidance, refer to our peptide reconstitution protocol.

For research use only. Not intended for human consumption, therapeutic use, or veterinary application. This product has not been evaluated by the FDA.

Research Guide

For a detailed scientific overview of this compound, read our research guide.